A Phase 3 interventional study of ACR16 and Placebo in Huntington's Disease, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 31 sites in 8 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-08-29.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Huntington Disease with a site in United Kingdom — 10 open to participants now, 15 under way, 3 of them phase 3. Huntington Disease · United Kingdom.
Among the 51 studies in Huntington Disease with a site in United Kingdom, this one is the 3rd largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2008, is one of 7 in phase 3, and was the 1st registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →10 of the 51 studies in Huntington Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Prilenia · Sites in United Kingdom, United States, Belgium and 9 more countries
Ages 23–65
Sarepta Therapeutics, Inc. · Sites in United Kingdom, Australia, New Zealand and 2 more countries
Ages 21–70
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United Kingdom, United States, Argentina and 7 more countries
Ages 25+
Alnylam Pharmaceuticals · Sites in United Kingdom, Canada, Germany
Ages 25–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 22 · Phase 3 8
First in 2004; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 437 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 92 across the 38 interventional studies, 154 across the 13 observational. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 6 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Huntington Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246941Hoffmann-La RocheA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease | 2026-12-01 |
| NCT02855476University College, LondonHDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease | 2027-04-30 |
| NCT03434548King's College LondonIMarkHD: in Vivo Longitudinal Imaging of HD Pathology | 2027-06-30 |
| NCT07536061Sarepta Therapeutics, Inc.A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies in Huntington Disease with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
The primary objective in the present study is to confirm whether ACR16 is efficacious in improving voluntary motor function in Huntington's disease based on the Unified Huntington"s Disease Rating Scale (UHDRS) subscale. These symptoms seem to be most important for the functional disability associated with the disorder. To achieve this, participants are randomized to ACR16 45 mg once daily, ACR16 45 mg twice daily, or placebo treatment in equal proportions in a parallel design for a treatment duration of 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a placebo capsule matching to ACR16 once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), placebo capsule will be taken twice daily as 2 separate doses.
Drug: Placebo
Participants will receive ACR16 45 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), one ACR16 45 mg capsule and one placebo capsule will be taken as 2 separate doses.
Drug: ACR16 · Drug: Placebo
Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), ACR16 45 mg capsule will be taken twice daily as 2 separate doses (total dose: 90 mg)
Drug: ACR16
Capsules will be swallowed whole with water.
Also known as: Pridopidine
Capsules will be swallowed whole with water.
Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at Week 26
The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS include dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items are rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranges from 0 to 52, with higher scores indicating more severe motor impairment.
Time frame: Baseline, Week 26
The UHDRS Functional Assessment at Week 26
The UHDRS Functional Assessment considers 25 items associated with functional problems. The participant scores 1 point for every item to which they respond positively (zero points for negative responses). Total score ranges from 0 (worst) to 25 (best). Higher scores indicate better functional ability.
Time frame: Week 26
Number of Participants With Clinical Global Impression - Improvement (CGI-I) Score
Global improvement is rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.
Time frame: Week 26
Change From Baseline in Stroop Word Reading Test at Week 26
The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.
Time frame: Baseline, Week 26
Change From Baseline in Total UHDRS Behavioral Assessment Score at Week 26
The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.
Time frame: Baseline, Week 26
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 26
HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0 to 42. Lower change from baseline scores indicate improvement.
Time frame: Baseline, Week 26
Randomized Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as AEs that began after ACR16/placebo administration through week 26 or up to week 30 for participants not continuing in the open-label period. AEs included both serious adverse events (SAEs) and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Time frame: Baseline up to Week 30
Open-label Phase: Number of Participants With TEAEs
An AE was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration through Week 56. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Time frame: Week 26 up to Week 56
| Milestone | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| Started | 144 | 148 | 145 |
| Received at least 1 dose of study drug | 144 | 148 | 145 |
| Completed | 126 | 136 | 124 |
| Not completed | 18 | 12 | 21 |
| Withdrew: Adverse event | 13 | 9 | 15 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 2 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Other than specified | 0 | 0 | 1 |
| Milestone | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| Started | 113 | 125 | 115 |
| Completed | 97 | 108 | 100 |
| Not completed | 16 | 17 | 15 |
| Withdrew: Adverse event | 8 | 11 | 7 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 2 |
| Withdrew: Withdrawal by subject | 5 | 3 | 4 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Other than specified | 0 | 0 | 2 |
The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS include dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items are rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranges from 0 to 52, with higher scores indicating more severe motor impairment.
| units on a scale | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at Week 26 | 0.27 ± 4.43 | -0.23 ± 4.12 | -0.94 ± 3.87 |
The UHDRS Functional Assessment considers 25 items associated with functional problems. The participant scores 1 point for every item to which they respond positively (zero points for negative responses). Total score ranges from 0 (worst) to 25 (best). Higher scores indicate better functional ability.
| Units on a Scale | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| The UHDRS Functional Assessment at Week 26 | 16.81 ± 6.20 | 17.50 ± 5.73 | 17.48 ± 5.43 |
Global improvement is rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.
| Participants | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| Very much improved | 1 | 1 | 1 |
| Much improved | 8 | 8 | 7 |
| Minimally improved | 30 | 32 | 33 |
| No change | 55 | 59 | 50 |
| Minimally worse | 38 | 37 | 46 |
| Much worse | 7 | 9 | 2 |
| Very much worse | 0 | 0 | 0 |
| Missing | 0 | 0 | 1 |
The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.
| correct responses | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| Change From Baseline in Stroop Word Reading Test at Week 26 | -1.3 ± 11.9 | -1.1 ± 10.3 | -0.8 ± 11.7 |
The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.
| units on a scale | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| Change From Baseline in Total UHDRS Behavioral Assessment Score at Week 26 | 0.12 ± 13.51 | -0.41 ± 16.78 | -2.22 ± 10.84 |
HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0 to 42. Lower change from baseline scores indicate improvement.
| units on a scale | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg |
|---|---|---|---|
| Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 26 | -0.10 ± 6.04 | -0.73 ± 6.78 | 0.13 ± 6.00 |
An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as AEs that began after ACR16/placebo administration through week 26 or up to week 30 for participants not continuing in the open-label period. AEs included both serious adverse events (SAEs) and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Participants | Randomized Phase: Placebo | Randomized Phase: ACR16 45 mg | Randomized Phase: ACR16 90 mg |
|---|---|---|---|
| Randomized Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 92 | 91 | 99 |
An AE was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration through Week 56. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Participants | Open-label Phase: Placebo/ACR16 90 mg | Open-label Phase: ACR16 45 mg/90 mg | Open-label Phase: ACR16 90 mg/90 mg |
|---|---|---|---|
| Open-label Phase: Number of Participants With TEAEs | 90 | 101 | 95 |
Collected over Baseline up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Phase: Placebo | — | 11/144 (7.6%) | 54/144 (37.5%) |
| Randomized Phase: ACR16 45 mg | — | 10/148 (6.8%) | 49/148 (33.1%) |
| Randomized Phase: ACR16 90 mg | — | 9/145 (6.2%) | 56/145 (38.6%) |
| Open Label Phase: Placebo | — | 6/113 (5.3%) | 38/113 (33.6%) |
| Open Label Phase: ACR 16 | — | 15/240 (6.3%) | 88/240 (36.7%) |
| Event | Randomized Phase: Placebo | Randomized Phase: ACR16 45 mg | Randomized Phase: ACR16 90 mg | Open Label Phase: Placebo | Open Label Phase: ACR 16 |
|---|---|---|---|---|---|
| SUICIDE ATTEMPTPsychiatric disorders | 1/144 | 0/148 | 2/145 | 0/113 | 0/240 |
| DISEASE PROGRESSIONGeneral disorders | 1/144 | 0/148 | 0/145 | 1/113 | 0/240 |
| AGITATIONPsychiatric disorders | 0/144 | 0/148 | 1/145 | 1/113 | 2/240 |
| GASTROENTERITISInfections and infestations | 0/144 | 0/148 | 0/145 | 1/113 | 0/240 |
| HEAD INJURYInjury, poisoning and procedural complications | 0/144 | 0/148 | 0/145 | 1/113 | 0/240 |
| BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/144 | 0/148 | 0/145 | 1/113 | 0/240 |
| MAJOR DEPRESSIONPsychiatric disorders | 0/144 | 0/148 | 0/145 | 1/113 | 1/240 |
| ANAL SPASMGastrointestinal disorders | 1/144 | 0/148 | 0/145 | 0/113 | 0/240 |
| CONSTIPATIONGastrointestinal disorders | 1/144 | 0/148 | 0/145 | 0/113 | 0/240 |
| ALCOHOL POISONINGInjury, poisoning and procedural complications | 1/144 | 0/148 | 0/145 | 0/113 | 0/240 |
| Event | Randomized Phase: Placebo | Randomized Phase: ACR16 45 mg | Randomized Phase: ACR16 90 mg | Open Label Phase: Placebo | Open Label Phase: ACR 16 |
|---|---|---|---|---|---|
| FALLInjury, poisoning and procedural complications | 12/144 | 7/148 | 15/145 | 14/113 | 24/240 |
| HUNTINGTON'S CHOREACongenital, familial and genetic disorders | 9/144 | 7/148 | 10/145 | 7/113 | 29/240 |
| NASOPHARYNGITISInfections and infestations | 6/144 | 9/148 | 10/145 | 5/113 | 9/240 |
| DIARRHOEAGastrointestinal disorders | 7/144 | 10/148 | 9/145 | 3/113 | 8/240 |
| DIZZINESSNervous system disorders | 6/144 | 10/148 | 8/145 | 4/113 | 6/240 |
| NAUSEAGastrointestinal disorders | 9/144 | 9/148 | 5/145 | 2/113 | 5/240 |
| FATIGUEGeneral disorders | 9/144 | 7/148 | 4/145 | 4/113 | 6/240 |
| INSOMNIAPsychiatric disorders | 5/144 | 5/148 | 9/145 | 3/113 | 8/240 |
| DEPRESSIONPsychiatric disorders | 8/144 | 6/148 | 6/145 | 4/113 | 11/240 |
| HEADACHENervous system disorders | 4/144 | 4/148 | 8/145 | 4/113 | 4/240 |
Full analysis set included all randomized participants who received at least 1 dose of study drug and had undergone at least 1 clinical assessment post randomization.
| Age, Continuous(years) | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg | Total |
|---|---|---|---|---|
| Mean | 49.1 ± 9.6 | 51.0 ± 10.7 | 51.8 ± 11.1 | 50.6 ± 10.5 |
| Sex: Female, Male(Participants) | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg | Total |
|---|---|---|---|---|
| Female | 76 | 82 | 64 | 222 |
| Male | 68 | 66 | 81 | 215 |
| Race/Ethnicity, Customized(Participants) | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg | Total |
|---|---|---|---|---|
| Race — Asian | 0 | 2 | 0 | 2 |
| Race — Other | 0 | 1 | 0 | 1 |
| Race — Caucasian | 144 | 145 | 145 | 434 |
| Unified Huntington's Disease Rating Scale (UHDRS) Modified Motor Score (mMS)(units on a scale) | Placebo/ACR16 90 mg | ACR16 45 mg/90 mg | ACR16 90 mg/90 mg | Total |
|---|---|---|---|---|
| Mean | 19.43 ± 8.28 | 18.38 ± 6.76 | 18.57 ± 6.90 | 18.79 ± 7.34 |
Ran from Apr 2008 to primary completion in Jun 2010, 25 months.
Results were first posted in Aug 2023, 13 years 2 months after primary completion. A results delay was requested in Feb 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Teva Branded Pharmaceutical Products R&D, Inc. →